Market Chatter: JD.com Facing Criticism Over Concessions to Clear Ceconomy Acquisition in EU
MT newswire2026/09/11 08:49Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Vertex Pharmaceuticals shares rise after raising 2026 revenue forecast
Tenuis: Apple achieves growth in most markets in the fourth fiscal quarter

Palantir's Q3 revenue doubles, U.S. commercial income surpasses government income for the first time, full-year guidance significantly raised | Earnings Report Insights
Palantir’s Q3 revenue reached $2.313 billion, marking a 96% year-on-year increase and surpassing the market expectation of $2.18 billion. U.S. commercial revenue stood at $984 million, soaring 148% year-on-year and exceeding the expected $937 million. For the first time, it surpassed U.S. government revenue, which was $953 million. Adjusted earnings per share were $0.44, higher than the estimated $0.41. The company raised its full-year revenue forecast to between $8.53 billion and $8.534 billion, above the market consensus of $8.2 billion.

BUZZ-BioMarin Pharma shares fall after lowering annual performance expectations